Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

HFrEF Polypill in Sri Lanka RCT

25. srpna 2026 aktualizováno: Anubha Agarwal, Washington University School of Medicine

Heart Failure With Reduced Ejection Fraction Polypill in Sri Lanka: A Multi-Center Type I Hybrid Randomized Controlled Trial

The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations, compared with usual care over a minimum of 12-months of follow-up.

Primary outcome of the study:

1) Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study duration

Secondary outcomes of the study:

  1. Rate of cardiovascular disease mortality over study duration
  2. Rate of recurrent heart failure hospitalizations over the study duration
  3. Rate of all-cause mortality over the study duration
  4. Change in left ventricular ejection fraction at 12-months and end of study assessed by transthoracic echocardiogram
  5. Change in BNP levels at 12 months and end of study
  6. Change in overall and domain specific health-related quality of life at 12-months and end of study assessed by a translated validated version of the Kansas City Cardiomyopathy Questionnaire (KCCQ-23)
  7. Change in physician-reported New York Heart Association class at 12-months and end of study
  8. Adherence to guideline-directed medical therapy assessed by pill count and MARS-5 questionnaire at baseline, 1-, 6-, 12-months, and end of study. Persistence assessed as continuation of assigned therapy at each follow-up visit. Dose optimization assessed as proportion achieving target doses (Strength 3 of the polypill, or comparable individual GDMT doses in the comparator arm) at 6-, 12-months, and end of study.

Safety outcomes:

  1. Proportion of participants with serious adverse events according to Good Clinical Practice guidelines over study duration
  2. Proportion of participants with adverse events of special interest over study duration
  3. Proportion of participants with adverse events leading to HF drug discontinuation over study duration
  4. Mean change from baseline to 12-months and end of study in serum potassium (mEq/L)
  5. Mean change from baseline to 12-months and end of study in serum creatinine (mg/dL)

Participants will be randomly assigned 1:1 stratified by sex and site to one of two groups, intervention (experimental arm) or usual care (control arm). The intervention group will be given four guideline-recommended medications for heart failure with reduced ejection fraction, combined in one over-encapsulated pill, with three dose strength options. Both groups will be observed over a minimum of 12-months of follow-up to assess key outcomes.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

The study intervention will be a heart failure with reduced ejection fraction (HFrEF) polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the over-encapsulation method and will undergo extensive stability testing to ensure quality. There will be 3 strengths of the HFrEF polypill available to facilitate initiation with low dose to prioritize clinical tolerability and laboratory safety and titration to higher doses of the HFrEF polypill. The dose of initiation and titration will be at the investigator's discretion. The HFrEF polypill will be delivered by licensed physicians responsible for managing heart failure at participating sites. Eligible providers must have formal medical qualifications in Sri Lanka and be actively involved in the care of patients with HFrEF. This includes cardiologists, internists, or general practitioners with experience in heart failure management. All participating physicians will receive standardized training on the study protocol including titration protocol, HFrEF polypill composition, and guidance for patient counseling prior to trial initiation to ensure consistent and accurate delivery of the intervention. Participants receiving the HFrEF polypill will also receive a "HFrEF polypill card" that delineates the drugs and doses included in the HFrEF polypill combination and contact information for the local study team in case of hospitalization at another facility.

HFrEF polypill combinations by strength:

HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg HFrEF polypill strength 3: bisoprolol 10 mg + losartan 100 + eplerenone 50 mg + dapagliflozin 10 mg

Participants in the comparator control group will receive usual care from their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines. Participants in the intervention group will be provided with the HFrEF polypill by the study, and participants in the control group will be provided HFrEF medications through the pharmacy at the public hospital site(s) in Sri Lanka where they are generally free of cost.

Typ studie

Intervenční

Zápis (Odhadovaný)

1672

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Anubha Agarwal, MD MSc
  • Telefonní číslo: +1 314-362-1291
  • E-mail: anubha@wustl.edu

Studijní záloha kontaktů

  • Jméno: Asita de Silva, MBBS DPhil FRCP
  • Telefonní číslo: +94 11 2961241
  • E-mail: asita@kln.ac.lk

Studijní místa

  • Srí Lanka
    • Central Province
      • Kandy, Central Province, Srí Lanka, 20000
        • Nábor
        • National Hospital Kandy
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Zanoona Siddeek
    • North Western Province
      • Kurunegala, North Western Province, Srí Lanka, 60000
        • Zatím nenabíráme
        • Teaching Hospital Kurunegala
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Aruna Jayawarna
    • Northern Province
      • Jaffna, Northern Province, Srí Lanka, 40000
        • Nábor
        • Teaching Hospital Jaffna
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Thepana Sasiharan
        • Dílčí vyšetřovatel:
          • Sebastian Heavenly
    • Ratnapura
      • Colombo, Ratnapura, Srí Lanka, 70000
        • Zatím nenabíráme
        • Rathnapura Teaching Hospital
        • Kontakt:
    • Southern Province
      • Galle, Southern Province, Srí Lanka, 80000
        • Nábor
        • National Hospital Galle
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Piumi Rajawardhana
        • Dílčí vyšetřovatel:
          • T.G Sandamali
    • Western Province
      • Colombo, Western Province, Srí Lanka, 00100
        • Zatím nenabíráme
        • National Hospital of Sri Lanka
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Chandrike Ponnamperuma
        • Dílčí vyšetřovatel:
          • Thisal Semina
        • Dílčí vyšetřovatel:
          • Tanya Pereira
        • Dílčí vyšetřovatel:
          • Neranja Weerakoon
        • Dílčí vyšetřovatel:
          • Chandana Wijesingha
        • Dílčí vyšetřovatel:
          • Bhathiya Ranasinghe
      • Colombo, Western Province, Srí Lanka, 10290
        • Zatím nenabíráme
        • University Hospital - General Sir John Kotelawala Defence University
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Subash Karunarathna
        • Dílčí vyšetřovatel:
          • Sandali Wijewardena
        • Dílčí vyšetřovatel:
          • Gishara Hemachandra
        • Dílčí vyšetřovatel:
          • Sashini Amarasinghe
      • Dehiwala, Western Province, Srí Lanka, 10350
        • Nábor
        • Colombo South Teaching Hospital
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Geethani Gunasekara
      • Gampaha, Western Province, Srí Lanka, 11000
        • Zatím nenabíráme
        • Gampaha District General Hospital
        • Kontakt:
      • Negombo, Western Province, Srí Lanka, 11500
        • Zatím nenabíráme
        • District General Hospital Negombo
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Anusha de Silva
      • Ragama, Western Province, Srí Lanka, 11010
        • Nábor
        • Colombo North Teaching Hospital
        • Kontakt:
        • Dílčí vyšetřovatel:
          • Thushari Gunawardana
        • Dílčí vyšetřovatel:
          • Sinthi Sivarajah
        • Dílčí vyšetřovatel:
          • Anjalee Weerasuriya

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  1. Adults (≥18 years old)
  2. Diagnosis of heart failure with reduced ejection fraction (HFrEF) including clinical symptoms or clinical signs or natriuretic peptide elevation AND echocardiographic or other evidence of reduced left ventricular ejection fraction (EF ≤40%)
  3. New York Heart Association Class II, III, or IV symptoms

Exclusion Criteria:

  1. Known contraindication to any of the HFrEF polypill components (e.g., advanced renal disease, bradycardia, allergy, amongst others).
  2. Significant renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m2).
  3. Raised serum potassium >5 mEq/L.
  4. Symptomatic hypotension or systolic BP <100 mmHg as per the average of last 2 of the 3 measurements at visit 1.
  5. Symptomatic bradycardia or second or third-degree heart block without a pacemaker on ECG review at visit 1.
  6. History of type 1 diabetes mellitus.
  7. Women who are pregnant, breastfeeding or of childbearing potential and are not using and do not plan to continue using a highly acceptable form of contraception throughout the study (pharmacological or barrier methods).
  8. Concomitant illness, physical impairment or mental condition which in the opinion of the study team/ primary physician could interfere with the conduct of the study including outcome assessment.
  9. Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.
  10. Participant's responsible physician believes it is not appropriate for participant to participate in the study.
  11. Inability or unwillingness to provide written informed consent.
  12. Involvement in the planning and/or conduct of the study.
  13. Unable to complete study procedures and/or plan to move out of the study site area in the next 12 months.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Usual Care
Participants in the comparator control group will receive usual care from their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines. Participants will receive their HFrEF medications through the pharmacy at the sites, where guideline-directed medical therapy are dispensed without charge to participants when available on the public hospital formulary.
Jiný: Usual Care
Participants in the comparator control group will receive usual care from their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines. Participants will receive their HFrEF medications through the pharmacy at the sites, where guideline-directed medical therapy are dispensed without charge to participants when available on the public hospital formulary.
Experimentální: HFrEF Polypill

The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the over-encapsulation method. There will be 3 strengths of the HFrEF polypill available:

Strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 3: bisoprolol 10 mg + losartan 100 mg + eplerenone 50 mg + dapagliflozin 10 mg

Every intervention participant will be established on the highest tolerated strength of the HFrEF polypill, with Strength 3 as the target dose. Following initiation at the strength matched to the participant's background guideline-directed medical therapy, the polypill strength will be advanced by one level at each scheduled study visit aligned with the initiation and titration protocol.
Lék: HFrEF Polypill
The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the over-encapsulation method. There will be 3 strengths of the HFrEF polypill available: Strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 3: bisoprolol 10 mg + losartan 100 mg + eplerenone 50 mg + dapagliflozin 10 mg.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month study visits, and every 3 months thereafter through study completion, an average of 18 months.

Cardiovascular disease mortality is defined as death due to acute myocardial infarction, worsening heart failure, stroke, sudden cardiac death, arrhythmia, pulmonary embolism, cardiovascular procedures or their complications, other vascular causes, or any death of unknown cause unless a non-cardiovascular etiology is clearly established.

HF hospitalization is defined as any unplanned hospitalization for at least 24 hours, for which the primary cause is heart failure, accompanied by objective evidence of decompensation and requiring initiation or intensification of HF-specific therapy, occurring after a documented period of clinical stability of at least 12 hours since the prior HF event.

Adjudicated by the blinded Outcome Adjudication Committee.
1 month, 3 month, 6 month, 9 month, 12 month study visits, and every 3 months thereafter through study completion, an average of 18 months.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Rate of cardiovascular disease mortality over study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month study visits, and every 3 months thereafter, through study completion, an average of 18 months.

Cardiovascular disease mortality is defined as death due to acute myocardial infarction, worsening heart failure, stroke, sudden cardiac death, arrhythmia, pulmonary embolism, cardiovascular procedures or their complications, other vascular causes, or any death of unknown cause unless a non-cardiovascular etiology is clearly established.

Adjudicated by the blinded Outcome Adjudication Committee.
1 month, 3 month, 6 month, 9 month, 12 month study visits, and every 3 months thereafter, through study completion, an average of 18 months.
Rate of recurrent heart failure hospitalizations over the study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.

HF hospitalization is defined as any unplanned hospitalization for at least 24 hours, for which the primary cause is heart failure, accompanied by objective evidence of decompensation and requiring initiation or intensification of HF-specific therapy, occurring after a documented period of clinical stability of at least 12 hours since the prior HF event.

Adjudicated by the blinded Outcome Adjudication Committee.
1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Rate of all-cause mortality over the study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
All-cause mortality is defined as death due to any cause.
1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Change in left ventricular ejection fraction at 12-months and end of study assessed by transthoracic echocardiogram
Časové okno: Baseline, 12 months, and at study completion, an average of 18 months.
Baseline, 12 months, and at study completion, an average of 18 months.
Change in BNP levels at 12 months and end of study
Časové okno: Baseline, 12 months, and at study completion, an average of 18 months.
Baseline, 12 months, and at study completion, an average of 18 months.
Change in overall and domain specific health-related quality of life at 12-months and end of study
Časové okno: Baseline, 12 months, and at study completion, an average of 18 months.
Health-related quality of life (HRQoL) will be assessed by a translated validated Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23)
Baseline, 12 months, and at study completion, an average of 18 months.
Change in physician-reported New York Heart Association class at 12-months and end of study
Časové okno: Baseline, 12 months, and at study completion, an average of 18 months.
Baseline, 12 months, and at study completion, an average of 18 months.
Adherence to guideline-directed medical therapy, persistence and dose optimization
Časové okno: Baseline, 1, 6, 12 months, and at study completion, an average of 18 months

Adherence to guideline-directed medical therapy assessed by pill count and MARS-5 questionnaire.

Persistence assessed as continuation of assigned therapy at each follow-up visit.

Dose optimization assessed as proportion achieving target doses (Strength 3 of the polypill, or comparable individual GDMT doses in the comparator arm) at 6-, 12-months, and end of study.
Baseline, 1, 6, 12 months, and at study completion, an average of 18 months

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of participants with serious adverse events according to Good Clinical Practice guidelines over study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Proportion of participants with serious adverse events according to Good Clinical Practice (GCP) guidelines (ICH E6 [R3]) over the study duration.
1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Proportion of participants with adverse events of special interest over study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.

Adverse events of special interest:

  1. symptomatic hypotension
  2. diabetic ketoacidosis
  3. severe hypoglycemia
  4. lower limb amputation
  5. hyperkalemia
  6. worsening renal function
  7. falls
1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Proportion of participants with adverse events leading to HF drug discontinuation over study duration
Časové okno: 1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
1 month, 3 month, 6 month, 9 month, 12 month visit, and thereafter every 3 months, through study completion, an average of 18 months.
Mean change from baseline to 12-months and end of study in serum potassium (mEq/L)
Časové okno: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, and at study completion, an average of 18 months.
Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, and at study completion, an average of 18 months.
Mean change from baseline to 12-months and end of study in serum creatinine (mg/dL)
Časové okno: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, and at study completion, an average of 18 months.
Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, and at study completion, an average of 18 months.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Washington University School of Medicine

Spolupracovníci

National Heart, Lung, and Blood Institute (NHLBI)
Centre for Chronic Disease Control, India
University of Kelaniya
The George Institute
RemediumOne

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Užitečné odkazy

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

17. srpna 2026

Primární dokončení (Odhadovaný)

1. dubna 2029

Dokončení studie (Odhadovaný)

1. dubna 2029

Termíny zápisu do studia

První předloženo

11. února 2026

První předloženo, které splnilo kritéria kontroly kvality

1. května 2026

První zveřejněno (Aktuální)

6. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

28. srpna 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

25. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 202605087

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

De-identified participant-level data and accompanying data dictionaries will be made available to qualified investigators upon reasonable request and following approval by the Steering Committee, consistent with NIH data-sharing policies. Requests must include a methodologically sound proposal and a data use agreement ensuring participant confidentiality.

Časový rámec sdílení IPD

De-identified individual participant data will become available after publication of the primary results manuscript and remain available thereafter, subject to Steering Committee approval of each request.

Kritéria přístupu pro sdílení IPD

Qualified investigators may request access by submitting a methodologically sound proposal to the study Steering Committee. Approved requests require a signed data use agreement ensuring participant confidentiality, consistent with NIH data-sharing policies.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit